Cannabis Dependence Risk and Your Genetics

By the ExomeDNA Research Team

This page contains general information only. For personal health decisions, consult a qualified clinician.

Cannabis use disorder is a clinical condition in which a person finds it difficult to control or reduce cannabis use despite experiencing negative consequences in health, relationships, or daily functioning. Genetic variation contributes to individual differences in susceptibility, influencing the brain’s reward circuitry, neuroplasticity, and stress-response systems. Research base: Robust.

What is cannabis dependence risk?

Cannabis use disorder affects a meaningful proportion of people who use cannabis regularly. It is characterized by continued use despite negative social, occupational, or health effects; difficulty cutting down; and, in some cases, tolerance and withdrawal symptoms. Not everyone who uses cannabis develops dependence — individual susceptibility varies considerably, and genetic factors are one piece of a larger puzzle that includes age of first use, frequency of use, mental health history, social environment, and access to support.

A higher genetic score on this trait reflects a stronger statistical signal in the direction of cannabis dependence susceptibility. It does not predict that any individual will develop cannabis use disorder. Many people with an elevated genetic signal never develop problematic use, particularly when protective environmental and social factors are present. Conversely, cannabis use disorder can develop in people with lower genetic scores when environmental exposures are significant.

Population studies suggest that approximately 9% of people who ever use cannabis will develop cannabis use disorder at some point. Among those who use cannabis daily, estimates rise to approximately 25–50%. (Reference: epidemiological literature broadly; no single PMID cited here.)

The genetics behind cannabis dependence risk

The genetic architecture of cannabis dependence risk is complex, involving many common variants each contributing small effects. Several genes in or near associated genomic regions have known roles in brain function, reward learning, and inhibitory control.

BDNF — the neuroplasticity foundation

BDNF (brain-derived neurotrophic factor) is among the most biologically relevant genes associated with this trait. BDNF encodes a neurotrophin — a protein that promotes the survival, growth, and differentiation of neurons. In the brain’s reward circuitry, particularly the mesolimbic dopamine pathway connecting the ventral tegmental area to the nucleus accumbens and prefrontal cortex, BDNF signaling regulates how strongly reward associations are encoded and maintained.

When reward experiences are repeated, BDNF facilitates synaptic plasticity and long-term potentiation in circuits that encode those associations. Cannabis directly interacts with endocannabinoid receptors distributed throughout these same regions, and chronic cannabis exposure modulates BDNF expression. Genetic variation in BDNF influences the neuroplasticity substrate upon which cannabis acts — in other words, it may shape how readily the brain forms and strengthens reward-related memories tied to cannabis use.

BDNF-AS — an epigenetic regulatory layer

BDNF-AS encodes a long non-coding RNA transcribed from the antisense strand of the BDNF gene. This RNA molecule acts as a regulator of BDNF expression itself: changes in BDNF-AS levels modulate how much BDNF protein is ultimately available in neurons. This antisense regulation adds an epigenetic dimension to the BDNF story — variation in BDNF-AS may fine-tune neurotrophin availability in reward circuits, with downstream effects on addiction vulnerability.

CADM2 — synaptic adhesion and behavioral inhibition

CADM2 (cell adhesion molecule 2) encodes a synaptic adhesion protein expressed in neurons throughout the brain. Variants near CADM2 have appeared across genome-wide studies of multiple substance use traits, externalizing behaviors, and risk-taking phenotypes. The consistent cross-trait association suggests that this genomic region may influence a broader dimension of behavioral inhibition and impulse control — a domain relevant to the development and maintenance of substance use disorders, including cannabis use disorder.

BARHL2 — GABAergic inhibitory circuitry

BARHL2 is a homeodomain transcription factor expressed in the developing and adult brain, with a role in the specification of GABAergic interneurons. GABAergic interneurons are the brain’s primary inhibitory neurons — they modulate the activity of excitatory circuits, including those involved in reward and impulse control. Disruption of inhibitory tone in prefrontal and reward regions is a feature of substance use disorders, and genes involved in GABAergic specification like BARHL2 represent a plausible biological pathway.

ARID5B — chromatin remodeling in neural contexts

ARID5B is a member of the AT-rich interaction domain family of DNA-binding proteins. It participates in chromatin remodeling — the process by which the physical structure of DNA is reorganized to regulate gene expression. In neural contexts, chromatin remodeling governs the accessibility of genes involved in reward learning, stress response, and synaptic adaptation. Variation in ARID5B may affect transcriptional programs relevant to how the brain responds to repeated drug exposure.

What the research says

Two large-scale genomic studies provide the evidence base for this trait’s genetic associations.

Levey et al. (2023), published in Nature Genetics, conducted a multi-ancestry genome-wide association study of cannabis use disorder involving hundreds of thousands of participants across multiple ancestries. The multi-ancestry design is a meaningful methodological strength: when associations replicate across diverse genetic backgrounds, confidence in the biological signal increases substantially compared to single-ancestry studies. This work identified multiple genome-wide significant loci and offered insight into the biological pathways involved in cannabis use disorder, including neural and behavioral mechanisms.

The Levey 2023 multi-ancestry study identified genome-wide significant associations at multiple loci, with findings replicated across ancestrally diverse cohorts — a design that strengthens confidence in the biological signals identified. (PMID: 37985822)

Xu et al. (2023), published in Addiction, applied a multi-trait analysis of GWAS (MTAG) framework to substance use traits simultaneously. This approach leverages genetic correlation across related phenotypes to boost statistical power and reveal shared genetic architecture. A key finding relevant to cannabis dependence risk is that some of the genetic risk variants overlap with those for other substance use traits — suggesting shared neurobiological vulnerability pathways that cut across specific substances. This cross-substance genetic overlap has implications for understanding why some individuals are broadly susceptible to substance use disorders rather than disorder-specific ones.

Taken together, these studies support a robust genetic signal for cannabis dependence risk. Associations have been identified across multiple large cohorts and ancestries, and the underlying biology points to neurotrophic signaling, synaptic plasticity, inhibitory control, and behavioral regulation as key mechanisms.

Research base: Robust.

How cannabis dependence risk affects you

A higher genetic score on cannabis dependence risk reflects a stronger statistical tendency, at the population level, toward susceptibility to cannabis use disorder. Understanding what this means in practice requires holding two things in mind simultaneously.

First, genetics is not destiny. The transition from cannabis use to cannabis use disorder involves a complex interplay of genetic predisposition, age of initiation (earlier initiation is associated with higher risk, likely because the adolescent brain is more sensitive to cannabis effects on neurodevelopment), frequency and quantity of use, potency of the cannabis used (high-THC products carry different risk profiles than lower-potency preparations), co-occurring mental health conditions such as anxiety, depression, or ADHD, social environment and peer norms, and access to coping resources and social support.

Second, the biological pathways implicated — particularly BDNF-mediated neuroplasticity in the reward circuitry — are not fixed. Neuroplasticity is, by definition, modifiable. Exercise, sleep, stress management, and mental health treatment all influence BDNF signaling and the brain’s reward circuitry. This means that the biological substrate underlying genetic susceptibility is not static.

For individuals who use cannabis and have an elevated genetic score, awareness itself can be a protective tool — not as a source of alarm, but as information that supports more intentional choices about use patterns, timing, and context.

Working with your cannabis dependence risk result

If your result shows an elevated genetic signal for cannabis dependence risk, the most useful response is informed awareness rather than alarm. Several evidence-based strategies are relevant.

Awareness and monitoring. Understanding your genetic susceptibility can support more mindful attention to your own patterns of use. Signs that use may be becoming problematic — difficulty reducing use when desired, continued use despite negative consequences, using more than intended — are worth taking seriously, regardless of genetic score.

Delayed initiation. For those who have not yet begun using cannabis, particularly younger individuals whose brains are still developing, delayed initiation is one of the most robustly supported protective factors. The prefrontal cortex, which governs impulse control and decision-making, continues developing into the mid-20s.

Mental health support. Cannabis use disorder frequently co-occurs with anxiety, depression, trauma-related conditions, and ADHD. Treating underlying mental health conditions reduces the likelihood that cannabis is being used as a coping mechanism, which is one pathway to dependence.

Evidence-based treatments. If cannabis use has become difficult to control, effective treatments exist. Cognitive behavioral therapy (CBT) and motivational interviewing are the best-supported psychological interventions for cannabis use disorder. These approaches work by building awareness of use patterns, strengthening motivation for change, and developing alternative coping strategies.

Clinician consultation. A qualified clinician — physician, psychiatrist, or addiction specialist — can provide personalized guidance based on your full health history, not just your genetic score. If there are concerns about cannabis use, consulting a clinician is the appropriate next step.

This result is informational. It does not replace a clinical evaluation and should not be used to make health decisions in isolation.

Cannabis dependence risk does not exist in isolation — it shares genetic architecture with related traits and connects to broader neurobiological themes.

Related substance use and behavioral traits. The genetic overlap between cannabis dependence risk and alcohol use risk highlights shared vulnerability pathways in addiction biology. Individuals with elevated scores on one substance use trait may carry partially overlapping genetic risk for others. See also: Alcohol Use Risk After Trauma and Stress Resilience.

Anxiety and stress response. BDNF signaling connects cannabis dependence vulnerability to anxiety regulation. Elevated anxiety is both a risk factor for cannabis use (as a coping mechanism) and a consequence of heavy or chronic use. See: Anxiety Response.

Sleep and cognitive function. Cannabis use disorder frequently disrupts sleep architecture, and sleep quality in turn affects the brain’s reward and inhibitory systems. See: Sleep Quality and ADHD Tendency.

Key gene. BDNF is central to the neuroplasticity narrative underlying this trait. Learn more about how BDNF variation affects brain function across multiple traits: BDNF gene page.

The CADM2 region — associated here through its role in synaptic adhesion and behavioral inhibition — also appears in associations with a range of externalizing behavioral traits, underscoring the biological continuity between substance use disorders and broader dimensions of behavioral regulation.

Frequently asked questions

Q: Does a high genetic score mean I will develop cannabis use disorder? A: No. A higher score reflects a stronger statistical signal toward susceptibility at the population level — it does not predict any individual’s outcome. Many people with elevated genetic scores never develop cannabis use disorder, and environmental factors, choices about use, mental health support, and social context all play substantial roles. Genetics is one input among many.

Q: What genes are involved in cannabis dependence risk? A: Several genes in or near associated genomic regions have known roles in brain function relevant to this trait. BDNF and BDNF-AS are involved in neuroplasticity and reward circuitry signaling. CADM2 encodes a synaptic adhesion molecule associated with behavioral inhibition and substance use traits across multiple studies. BARHL2 is involved in the specification of GABAergic inhibitory interneurons, which regulate reward and impulse control circuits. ARID5B participates in chromatin remodeling that affects gene expression in neural contexts. ExomeDNA reports only genes from the authorized filtered list for this trait.

Q: Is cannabis dependence risk shared with other substance use disorders? A: Research supports partial genetic overlap between cannabis dependence risk and other substance use traits. A multi-trait analysis (Xu et al., 2023, PMID 37156939) found that some genetic variants associated with cannabis dependence risk are also associated with other substance use phenotypes, suggesting shared neurobiological vulnerability pathways. This does not mean all substance use disorders are the same — it means some genetic factors influence a broader susceptibility dimension.

Q: What is BDNF and why does it matter for cannabis dependence? A: BDNF stands for brain-derived neurotrophic factor. It is a protein that supports neuronal survival, synaptic plasticity, and long-term potentiation — the cellular processes by which memories and associations are strengthened. In the brain’s reward circuitry, BDNF signaling influences how powerfully reward experiences are encoded. Because cannabis acts on endocannabinoid receptors distributed throughout these same circuits, and because cannabis exposure directly modulates BDNF expression, genetic variation in BDNF may shape the neuroplasticity substrate upon which cannabis dependence develops. This makes BDNF one of the most biologically compelling genes in the cannabis dependence risk landscape.

Q: Can I do anything about my genetic risk? A: Yes — in the sense that genetic predisposition is not fixed destiny. The neuroplasticity mechanisms underlying this risk (particularly BDNF-related pathways) are influenced by modifiable factors including exercise, sleep quality, stress management, and mental health treatment. Evidence-based interventions for cannabis use disorder, including cognitive behavioral therapy and motivational interviewing, are effective regardless of genetic score. Delayed initiation, particularly during adolescence when brain development is ongoing, is one of the most supported protective behaviors. Consulting a qualified clinician is the appropriate step for personalized guidance.

Q: How confident is the research on cannabis dependence genetics? A: The confidence tier for this trait is Robust. Genetic associations have been identified across multiple large cohorts and replicated across ancestrally diverse populations (Levey et al., 2023, PMID 37985822). The multi-ancestry design of the primary study is a methodological strength that increases confidence compared to single-ancestry findings. Research base: Robust.

References

Xu K et al. (2023). Identifying genetic loci and phenomic associations of substance use traits: A multi-trait analysis of GWAS (MTAG) study. Addiction. DOI: 10.1111/add.16229. PMID: 37156939.
Levey DF et al. (2023). Multi-ancestry genome-wide association study of cannabis use disorder yields insight into disease biology and public health implications. Nature Genetics. DOI: 10.1038/s41588-023-01563-z. PMID: 37985822.

Data sources: Genome-wide association summary statistics were drawn from published peer-reviewed studies. Gene prioritization reflects positional mapping and published biological annotation from the primary cited literature.

ExomeDNA genetic results are for wellness and educational purposes only. Consult a clinician for personalized health guidance. Genetic results do not substitute for professional clinical evaluation.

Browse all traits →